Stephan Kurylas
Family Medicine · Crofton, MDNPI 1407883903
Payments from drug & device makers
Across 1,657 payments — averaging $21.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$4K
- Sanofi-aventis U.S. LLC$3K
- AbbVie$3K
- Amgen$2K
- GSK$2K
- Novo Nordisk$2K
- plus $19K from 54 others
What the payments were for
- Consulting fees$1,2003%
- Speaking & faculty fees$5001%
- Travel & lodging$720%
- Food & beverage$33,10795%
- Education$250%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$1,653
- FARXIGA$1,053
- SOLIQUA 100/33$866
- BREZTRI$846
- AIRSUPRA$814
- TOUJEO$583
- VRAYLAR$496
- REXULTI$478
- Confirm Rx$405
- Kerendia$376
- MOUNJARO$345
- TRELEGY ELLIPTA$254
- AIMOVIG$244
- Otezla$244
- AREXVY$234
- QELBREE$226
- VERQUVO$221
- BREZTRI AEROSPHERE$221
- RYBELSUS$205
- TZIELD$132
How this compares
$34,905 in reported general payments places this provider in the 95th percentile of 1,193 family medicine providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 144 | $203,685 |
| JardianceEmpagliflozin | 63 | $85,106 |
| FarxigaDapagliflozin Propanediol | 83 | $81,284 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 83 | $77,938 |
| TrulicityDulaglutide | 35 | $68,259 |
| MounjaroTirzepatide | 47 | $63,622 |
| EliquisApixaban | 33 | $44,554 |
| VascepaIcosapent Ethyl | 35 | $29,788 |
| XareltoRivaroxaban | 14 | $22,781 |
| KerendiaFinerenone | 12 | $20,663 |
| LinzessLinaclotide | 20 | $19,816 |
| Xigduo XrDapaglifloz Propaned/Metformin | 13 | $19,350 |
| GemtesaVibegron | 14 | $17,298 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 11 | $17,158 |
| MyrbetriqMirabegron | 21 | $16,091 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $2,015 | $203,685144 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $1,169 | $131,88082 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $411 | $102,26574 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Airsupra | $3,761 | $97,159110 claims |
| GSKTrelegy Ellipta | $2,299 | $77,93883 claims |
| PfizerEliquis | $543 | $44,55433 claims |
| Johnson & JohnsonXarelto | $165 | $22,78114 claims |
| AbbVieLinzess, Synthroid | $2,736 | $22,01956 claims |
| BayerKerendia | $848 | $20,66312 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $459 | $18,25635 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $175 | $17,29814 claims |
| Astellas Pharma US IncMyrbetriq | $97 | $16,09121 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,193 family medicine providers in Maryland.
Other family medicine in Crofton
- Stephen OngOxon Hill$5.9M
- Stephan BartWoodstock$1.7M
- Karen DonaldsonBaltimore$899K
- Rajiv DuaColumbia$765K
- Greg TampusLutherville Timonium$735K
- Louis JacquesBaltimore$522K
- Stephanie MellerOxon Hill$518K
- Sharon ChungGlen Burnie$333K
- Michael ObiefuneBaltimore$291K
- Thomas LawrenceBerlin$254K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.